89 related articles for article (PubMed ID: 2459780)
21. [Indications, technique and risks in bone marrow transplantation in adulthood].
Heyll A; Söhngen D; Minning H; Meckenstock G; Aul C; Schneider W
Praxis (Bern 1994); 1996 Mar; 85(12):378-86. PubMed ID: 8643901
[TBL] [Abstract][Full Text] [Related]
22. Interferons for the treatment of hematological malignancies.
Urabe A
Oncology; 1994; 51(2):137-41. PubMed ID: 7515169
[TBL] [Abstract][Full Text] [Related]
23. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
Reuben JM; Lee BN; Johnson H; Fritsche H; Kantarjian HM; Talpaz M
Clin Cancer Res; 2000 May; 6(5):1671-7. PubMed ID: 10815885
[TBL] [Abstract][Full Text] [Related]
24. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
25. Hairy-cell leukemia and alpha-interferon treatment: long-term responders.
Zinzani PL; Lauria F; Salvucci M; Rondelli D; Raspadori D; Bendandi M; Magagnoli M; Tura S
Haematologica; 1997; 82(2):152-5. PubMed ID: 9175317
[TBL] [Abstract][Full Text] [Related]
26. Clinical experience of antibodies to interferon-alpha during treatment of chronic myeloid leukemia.
Russo D; Candoni A; Grattoni R
J Interferon Cytokine Res; 1997 Jul; 17 Suppl 1():S47-9. PubMed ID: 9241616
[TBL] [Abstract][Full Text] [Related]
27. Alpha-interferon treatment of cutaneous T cell lymphoma and chronic lymphocytic leukemia.
Foon KA; Bunn PA
Semin Oncol; 1986 Dec; 13(4 Suppl 5):35-9. PubMed ID: 3541217
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
29. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
30. Interferon alpha in the treatment of chronic myelogenous leukemia.
Robak T
Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
[TBL] [Abstract][Full Text] [Related]
31. Clinical and biological activity of the interferons in hematologic malignancies.
Gutterman JU
Prog Clin Biol Res; 1989; 288():337-48. PubMed ID: 2470111
[No Abstract] [Full Text] [Related]
32. Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: the MD Anderson experience.
Khouri IF; Kantarjian HM; Talpaz M; Giralt S; Rios MO; Hester JP; Champlin RE; Deisseroth AB
Bone Marrow Transplant; 1996 May; 17(5):775-9. PubMed ID: 8733697
[TBL] [Abstract][Full Text] [Related]
33. Cytokine therapy for hematological malignancies.
Ezaki K; Tsuzuki M
Gan To Kagaku Ryoho; 1997 May; 24 Suppl 1():182-94. PubMed ID: 9210900
[TBL] [Abstract][Full Text] [Related]
34. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
35. Treatment of chronic myelogenous leukemia.
Giralt S; Kantarjian H; Talpaz M
Semin Oncol; 1995 Aug; 22(4):396-404. PubMed ID: 7638636
[TBL] [Abstract][Full Text] [Related]
36. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
[TBL] [Abstract][Full Text] [Related]
37. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
[TBL] [Abstract][Full Text] [Related]
38. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
39. Sequential treatment of hairy cell leukemia: a new role for interferon.
Golomb HM; Ratain MJ; Vardiman JW
Important Adv Oncol; 1986; ():311-21. PubMed ID: 2454218
[TBL] [Abstract][Full Text] [Related]
40. Biotherapy with interferon in hematologic malignancies.
Roth MS; Foon KA
Oncol Nurs Forum; 1987; 14(6 Suppl):16-22. PubMed ID: 2447569
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
